-
Mashup Score: 622ASCO 2025 - Breast Cancer Highlights: INAVO120, SERENA-6, VERITAC-2, DESTINY-Breast09, ASCENT-04 - 7 day(s) ago
In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain were joined by Dr. Erika Hamilton from the Sarah Cannon Research Institute, to cover the latest advancements in breast cancer research presented at the ASCO 2025 annual meeting.
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 753ASCO 2025 - GI Cancer Highlights: DYNAMIC III, ATOMIC, BREAKWATER, MATTERHORN, DESTINY Gastric04 - 13 day(s) ago
In this episode of the Oncology Brothers podcast, we dived into the significant updates from the ASCO 2025 annual meeting, focusing specifically on gastrointestinal (GI) malignancies.
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
GI Cancer Highlights from #ASCO25 w/ @CathyEngMD ✅ #DYNAMIC3 ✅ #ATOMIC ✅ #BREAKWATER ✅ #MATTERHORN ✅ #DESTINYGastric04 Full Discussion: - https://t.co/YDUF2oqmDM - Also on the “Oncology Brothers” podcast #gism @ASCO #OncTwitter #MedTwitter https://t.co/g76lAmxPuz
-
-
Mashup Score: 84ASCO 2025 Lung Cancer Highlights: CheckMate 816, ToD, NeoADAURA, IMforte, DeLLphi 304 - 20 day(s) ago
Read this insightful blog post on My Blog.
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
Lung Cancer Highlights from #ASCO25 w/ @StephenVLiu ✅ #CM816 ✅ Timings of ICI ✅ #neoADAURA ✅ #IMForte ✅ #DeLLphi304 Full Discussion: - https://t.co/52xiM5hTM9 - Also on the “Oncology Brothers” podcast #lcsm @ASCO #OncTwitter #MedTwitter https://t.co/sAOnmxkIP5
-
-
Mashup Score: 37Nivolumab plus Ipilimumab in Microsatellite-Instability–High (MSI-H) Metastatic Colorectal Cancer - 1 month(s) ago
In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain had the pleasure of speaking with Dr. Nicholas Hornstein, a GI medical oncologist from Northwell Health.
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
Ipi + Nivo is now approved in dMMR/MSI-H mCRC based off #CM8HW! Before #ASCO25, we had a chance to 🗣️ this trial, findings, dosing, single vs. dual ICI and AEs w/ @GIMedOnc Full 🗣️: ⭐️ https://t.co/UK67dXqk6w ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #gism #GiOnc https://t.co/JWswuTD4lr
-
-
Mashup Score: 60Managing Toxicities of EGFR Inhibitors: Afatinib, Amivantamab-Lazertinib, Osimertinib - 1 month(s) ago
In this episode of the Oncology Brothers podcast, we dived into the evolving landscape of anti-EGFR drugs used in non-small cell lung cancer (NSCLC) with EGFR mutations.
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
ToxCheck series: Common anti-EGFR drugs we use for mEGFR non-small cell #LungCancer w/ @GlopesMd ✅ Afatinib ✅ Osimertinib ✅ Amivantamab + Lazertinib Full discussion: ⭐️ https://t.co/pVb5RZd6uY ⭐️ Also on the “Oncology Brothers” podcast #lcsm #OncTwitter @OncUpdates https://t.co/zedtMtQZDy
-
-
Mashup Score: 41Blog Post - 1 month(s) ago
Read this insightful blog post on My Blog.
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
Treatment Algorithm series: Small Cell #LungCancer w/ @LealTiciana ✅ Limited Stage ✅ Extensive Stage ✅ Role of PCI ✅ Upcoming data at #ASCO25 Full discussion: ⭐️ https://t.co/JX0JpVJPB7 ⭐️ Also on the “Oncology Brothers” podcast #lcsm #OncTwitter @OncUpdates https://t.co/00eFKywZa3
-
-
Mashup Score: 22
In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain had the pleasure of speaking with Dr. Susan Scott, a thoracic medical oncologist from The Johns Hopkins Hospital
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
Treatment Algorithm series: mNSCLC w/ actionable mutations in 1L with @SusanScottMD ✅ EGFR ✅ ALK ✅ ROS1/BRAF/RET/NTRK/MetExon14 Full discussion: ⭐️ https://t.co/NMHqhqbxb8 ⭐️ “Oncology Brothers” podcast #lcsm #OncTwitter #LungCancer @OncUpdates https://t.co/g6Em7FmqzD
-
-
Mashup Score: 59How to Treat Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Targeted Mutations - 2 month(s) ago
Read this insightful blog post on My Blog.
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
Treatment Algorithm series: mNSCLC w/ no actionable mutations in 1L with @DrMarkAwad ✅ IO vs Chemo + IO vs dual ICI ✅ KRASG12C & HER2 ✅ 2L and beyond Full discussion: ⭐️ https://t.co/ye0fHYZuQq ⭐️ “Oncology Brothers” podcast #lcsm #OncTwitter #LungCancer @OncUpdates https://t.co/wYexj2ZHI5
-
-
Mashup Score: 34Managing Side Effects of HER2 Targeted Therapy - Zanidatamab & Trastuzumab deruxtecan (T-DXd) - 2 month(s) ago
In this episode of the Oncology Brothers podcast, we wrapped up our three-part CME series on HER2-positive biliary tract cancer.
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
HER2+ metastatic BTC Pt 3/3! Here we 🗣️ AEs, management, step down dosing for availabms Rx options (TDxD & Zanidatamab) w/ @rachnatshroff Full 📢: 🌟 https://t.co/8meErelqWF 🌟 https://t.co/RAd8Do9Zv6 🌟Also on the “Oncology Brothers” podcast! #OncTwitter #MedTwitter #gism https://t.co/YGNG7KYM5y
-
-
Mashup Score: 63Perioperative Durvalumab FDA Approval New Standard for Muscle Invasive Bladder Cancer - 2 month(s) ago
In this episode of the Oncology Brothers podcast, we dived into the recent FDA approval of durvalumab in combination with chemotherapy for resectable muscle-invasive bladder cancer
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet-
#Durvalumab is now approved in #resectable MIBC based off #NIAGARA study! We 🗣️ the design, findings, role of postOp IO, and sequencing w/ @tompowles1 Full 🗣️: ⭐️ https://t.co/ls4viyixGX ⭐️ Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter #gusm #BladderCancer https://t.co/1VU2hE8ipE
-
Breast Cancer Highlights from #ASCO25 w/ @ErikaHamilton9 ✅ #INAVO120 ✅ #SERENA6 ✅ #VERITCA2 ✅ #DESTINYBreast09 ✅ #ASCENT04 Full Discussion: - https://t.co/96dmdcgTAg - Also on the “Oncology Brothers” podcast #bcsm @ASCO #OncTwitter #MedTwitter https://t.co/70hHcelOyE